Ensysce Biosciences (ENSC)

Company Profile

ensysce biosciences, san diego, ca, is an integrated drug delivery company for both small and large molecules. to overcome the major problem of non-medical use of opioid products, ensysce is using its prodrug technology to improve abuse deterrent properties. the tap bio-md™ abuse deterrent and mpar™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. this abuse is the fastest growing drug problem in the u.s. and it leads to billions in healthcare costs annually. for additional information about ensysce biosciences please visit www.ensysce.com.

Company profile

Ticker

ENSC, ENSCW

Exchange

NASDAQ

Website

ensysce.com

CEO

Daniel B. Silvers

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

Leisure Acquisition Corp.

SEC CIK

0001716947

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Covistat, Inc. • EBI OpCo, Inc. • EBI Operating, Inc. ...

ENSC stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Submission of Matters to a Vote of Security Holders

28 Aug 23

8-K

Ensysce Biosciences Reports Second Quarter 2023 Financial Results

10 Aug 23

Additional proxy soliciting materials

Additional exhibits for listing

17 May 23

Withdrawal of amendment

Latest ownership filings

View all

HG Vora Capital Management, LLC

14 Feb 23

SC 13G/A

CVI Investments, Inc.

14 Feb 23

SC 13G

Lincoln Park Capital Fund, LLC

CVI Investments, Inc.

Financial summary

Financial statements Chart ENSC financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.83 mm	3.83 mm	3.83 mm	3.83 mm	3.83 mm	3.83 mm
Cash burn (monthly)	(no burn)	(no burn)	764.65 k	1.43 mm	1.04 mm	1.39 mm
Cash used (since last report)	n/a	n/a	2.16 mm	4.05 mm	2.92 mm	3.93 mm
Cash remaining	n/a	n/a	1.67 mm	-218.65 k	906.30 k	-102.53 k
Runway (months of cash)	n/a	n/a	2.2	-0.2	0.9	-0.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

ENSC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	11	12	-8.3%
Opened positions	4	4	–
Closed positions	5	9	-44.4%
Increased positions	1	0	NEW
Reduced positions	0	5	EXIT

13F shares	Current	Prev Q	Change
Total value	712.73 mm	64.19 mm	+1010.4%
Total shares	6.99 mm	6.61 mm	+5.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Silvers Daniel B.	2.88 mm	$2.50 mm	0.0%
Hydra LAC	1.87 mm	$27.07 mm	0.0%
Lincoln Park Capital Fund	1.50 mm	$1.17 mm	0.0%
CVI Investments	336.87 k	$0.00	0.0%
Sabby Management	322.30 k	$580.14 mm	NEW
Anson Funds Management	36.26 k	$65.27 mm	NEW
Gsa Capital Partners	17.55 k	$32.00 k	NEW
Vanguard	15.42 k	$27.75 mm	NEW
Tower Research Capital	3.90 k	$7.02 mm	+488.2%
BLK Blackrock	975.00	$1.76 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Sabby Management	322.30 k	+322.30 k	NEW
Anson Funds Management	36.26 k	+36.26 k	NEW
Gsa Capital Partners	17.55 k	+17.55 k	NEW
Vanguard	15.42 k	+15.42 k	NEW
Virtu Financial	0.00	-13.43 k	EXIT
Powell Investment Advisors	0.00	-3.33 k	EXIT
Tower Research Capital	3.90 k	+3.24 k	+488.2%
UBS UBS Group AG - Registered Shares	0.00	-2.54 k	EXIT
WFC Wells Fargo & Co.	0.00	-5.00	EXIT
JPM JPMorgan Chase & Co.	0.00	-1.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ENSC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Mar 23	Bob G Gower	Common Stock	Buy	Acquire P	No	No	0.4883	90,287	44.09 k	1,222,682
1 Mar 23	Bob G Gower	Common Stock	Buy	Acquire P	No	No	0.4777	270,000	128.98 k	1,132,395
28 Feb 23	Bob G Gower	Common Stock	Buy	Acquire P	No	No	0.4883	109,300	53.37 k	862,395
9 Dec 22	Bob G Gower		Buy	Acquire P	No	No	1.4	357,143	500.00 k	753,095
9 Dec 22	Bob G Gower	Common Stock	Grant	Acquire A	No	No	1.4	714,286	1.00 mm	716,365
23 Jun 22	Adam Levin	Stock Option Common Stock	Grant	Acquire A	No	No	0.425	15,000	6.38 k	35,000
23 Jun 22	Curtis Rosebraugh	Stock Option Common Stock	Grant	Acquire A	No	No	0.425	20,000	8.50 k	35,000